questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
Oxygénases
Dioxygenases
Jumonji Domain-Containing Histone Demethylases
Jumonji Domain-Containing Histone Demethylases : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Jumonji Domain-Containing Histone Demethylases : Questions médicales les plus fréquentes",
"headline": "Jumonji Domain-Containing Histone Demethylases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Jumonji Domain-Containing Histone Demethylases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-10",
"dateModified": "2025-04-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Jumonji Domain-Containing Histone Demethylases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Dioxygenases",
"url": "https://questionsmedicales.fr/mesh/D049308",
"about": {
"@type": "MedicalCondition",
"name": "Dioxygenases",
"code": {
"@type": "MedicalCode",
"code": "D049308",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.690.416"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Jumonji Domain-Containing Histone Demethylases",
"alternateName": "Jumonji Domain-Containing Histone Demethylases",
"code": {
"@type": "MedicalCode",
"code": "D056484",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Danica Galonić Fujimori",
"url": "https://questionsmedicales.fr/author/Danica%20Galoni%C4%87%20Fujimori",
"affiliation": {
"@type": "Organization",
"name": "Department of Cellular and Molecular Pharmacology, University of California San Francisco; San Francisco, CA 94158, USA; Department of Pharmaceutical Chemistry, University of California San Francisco; San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco; San Francisco, CA 94158, USA. Electronic address: danica.fujimori@ucsf.edu."
}
},
{
"@type": "Person",
"name": "James E Longbotham",
"url": "https://questionsmedicales.fr/author/James%20E%20Longbotham",
"affiliation": {
"@type": "Organization",
"name": "Department of Cellular and Molecular Pharmacology, University of California San Francisco, 600 16th Street, Genentech Hall, San Francisco, California 94158, United States."
}
},
{
"@type": "Person",
"name": "Feng Li",
"url": "https://questionsmedicales.fr/author/Feng%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC, Shenyang, China."
}
},
{
"@type": "Person",
"name": "Christopher J Schofield",
"url": "https://questionsmedicales.fr/author/Christopher%20J%20Schofield",
"affiliation": {
"@type": "Organization",
"name": "Chemistry Research Laboratory , University of Oxford , 12 Mansfield Road , Oxford OX1 3TA , United Kingdom."
}
},
{
"@type": "Person",
"name": "Anthony Tumber",
"url": "https://questionsmedicales.fr/author/Anthony%20Tumber",
"affiliation": {
"@type": "Organization",
"name": "Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford 12 Mansfield Road OX1 3TA Oxford UK christopher.schofield@chem.ox.ac.uk lennart.brewitz@chem.ox.ac.uk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Fibrous protein composite scaffolds (3D) for tissue regeneration: An in vitro study on skeletal muscle regeneration.",
"datePublished": "2022-06-26",
"url": "https://questionsmedicales.fr/article/35816880",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.colsurfb.2022.112656"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clearance of defective muscle stem cells by senolytics restores myogenesis in myotonic dystrophy type 1.",
"datePublished": "2023-07-19",
"url": "https://questionsmedicales.fr/article/37468473",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-023-39663-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Human skeletal muscle organoids model fetal myogenesis and sustain uncommitted PAX7 myogenic progenitors.",
"datePublished": "2023-11-14",
"url": "https://questionsmedicales.fr/article/37963071",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7554/eLife.87081"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ascorbic acid reduces Ropivacaine-induced myotoxicity in cultured human osteoporotic skeletal muscle cells.",
"datePublished": "2023-07-15",
"url": "https://questionsmedicales.fr/article/37454045",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12891-023-06702-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "From cyclins to CDKIs: Cell cycle regulation of skeletal muscle stem cell quiescence and activation.",
"datePublished": "2022-08-02",
"url": "https://questionsmedicales.fr/article/35931143",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.yexcr.2022.113275"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Oxygénases",
"item": "https://questionsmedicales.fr/mesh/D010105"
},
{
"@type": "ListItem",
"position": 6,
"name": "Dioxygenases",
"item": "https://questionsmedicales.fr/mesh/D049308"
},
{
"@type": "ListItem",
"position": 7,
"name": "Jumonji Domain-Containing Histone Demethylases",
"item": "https://questionsmedicales.fr/mesh/D056484"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Jumonji Domain-Containing Histone Demethylases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Jumonji Domain-Containing Histone Demethylases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Jumonji Domain-Containing Histone Demethylases",
"description": "Comment diagnostiquer une dysfonction des Jumonji ?\nQuels marqueurs biologiques sont associés aux Jumonji ?\nLes biopsies sont-elles utiles pour le diagnostic ?\nQuels tests sanguins sont recommandés ?\nY a-t-il des tests d'imagerie pour ces enzymes ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Muscle+Development&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quels symptômes sont liés aux anomalies des Jumonji ?\nLes troubles neurologiques sont-ils associés ?\nY a-t-il des symptômes cutanés associés ?\nLes symptômes varient-ils selon le type de Jumonji ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Muscle+Development&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Jumonji Domain-Containing Histone Demethylases",
"description": "Peut-on prévenir les dysfonctionnements des Jumonji ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nY a-t-il des vaccins pour prévenir ces dysfonctionnements ?\nL'éducation génétique est-elle importante ?\nLes conseils diététiques peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Muscle+Development&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quels traitements sont disponibles pour les dysfonctionnements des Jumonji ?\nLes médicaments peuvent-ils cibler les Jumonji ?\nY a-t-il des traitements naturels recommandés ?\nLes traitements sont-ils personnalisés ?\nLes thérapies combinées sont-elles efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Muscle+Development&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quelles complications peuvent survenir avec les dysfonctionnements des Jumonji ?\nLes complications sont-elles graves ?\nY a-t-il des complications à long terme ?\nLes complications sont-elles réversibles ?\nLes complications varient-elles selon le type de Jumonji ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Muscle+Development&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quels sont les facteurs de risque pour les dysfonctionnements des Jumonji ?\nL'âge est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'exposition à des toxines est-elle un facteur ?\nLe mode de vie influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Muscle+Development&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des Jumonji ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux Jumonji ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de méthylation des histones et l'expression des gènes sont des marqueurs clés."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles utiles pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les biopsies peuvent aider à évaluer l'expression des Jumonji dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont recommandés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests pour mesurer les niveaux de protéines associées aux Jumonji peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests d'imagerie pour ces enzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'imagerie ne permet pas de diagnostiquer directement les Jumonji."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux anomalies des Jumonji ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de croissance, des anomalies développementales et des cancers peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils associés ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements neurologiques peuvent être liés à des mutations des Jumonji."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies cutanées peuvent être observées, notamment dans des syndromes spécifiques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de Jumonji ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, différents types de Jumonji peuvent entraîner des symptômes variés selon leur fonction."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la gravité et de la nature de la dysfonction des Jumonji."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des Jumonji ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les individus à risque de dysfonctionnements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir ces dysfonctionnements ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des Jumonji."
}
},
{
"@type": "Question",
"name": "L'éducation génétique est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur les risques génétiques peut aider à la prévention et à la détection précoce."
}
},
{
"@type": "Question",
"name": "Les conseils diététiques peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé cellulaire, mais ne prévient pas directement."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les dysfonctionnements des Jumonji ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des inhibiteurs spécifiques sont en cours d'étude."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils cibler les Jumonji ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments expérimentaux ciblent les Jumonji pour traiter des cancers."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels recommandés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches nutritionnelles et phytothérapeutiques sont explorées, mais peu prouvées."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des Jumonji."
}
},
{
"@type": "Question",
"name": "Les thérapies combinées sont-elles efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que les thérapies combinées peuvent améliorer les résultats cliniques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les dysfonctionnements des Jumonji ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cancers, des troubles métaboliques et des anomalies développementales peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent être potentiellement mortelles si non traitées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications chroniques peuvent se développer, affectant la qualité de vie."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de Jumonji ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier en fonction du type de Jumonji impliqué."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les dysfonctionnements des Jumonji ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs génétiques, environnementaux et liés au mode de vie peuvent influencer le risque."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains dysfonctionnements des Jumonji sont plus fréquents avec l'âge."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines est-elle un facteur ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines peut augmenter le risque de dysfonctionnements."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut accroître le risque de dysfonctionnements des Jumonji."
}
}
]
}
]
}
The present study explores the differentiation of myoblasts in bioengineered 3D composite scaffolds containing keratin and gelatin. Based on the composition and rheological properties three different ...
Muscle stem cells, the engine of muscle repair, are affected in myotonic dystrophy type 1 (DM1); however, the underlying molecular mechanism and the impact on the disease severity are still elusive. H...
In vitro culture systems that structurally model human myogenesis and promote PAX7...
Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable burden on society. Bone and muscle repre...
Primary human myoblasts and myotubes from healthy subjects, osteoarthritic and osteoporotic patients (OP) were cultured in the presence of Ropivacaine. In some experiments, ascorbic acid (AsA) was add...
A dose-dependent decrease of cell viability was observed after Ropivacaine exposure in both OP myoblasts and myotubes cultures, whereas those effects were not observed in the presence of Propofol, a g...
Our findings highlight the oxidative stress-mediated myotoxic effect of Ropivacaine on human skeletal muscle tissue cell cultures, and suggest treatment with AsA as valid strategy to mitigate its nega...
After extensive proliferation during development, the adult skeletal muscle cells remain outside the cell cycle, either as post-mitotic myofibers or as quiescent muscle stem cells (MuSCs, also known a...
Muscle-derived stem cells (MDSCs) contribute to the repair of injured muscles. However, the myogenicity of MDSCs generated from patients with Duchenne muscular dystrophy (DMD) relative to healthy indi...
A human DMD model was established using the stem cells prepared from muscle derived from patients with DMD (DMD-hMDSCs). The expression of myogenic lineage-specific markers in MDSCs was examined with ...
It was demonstrated that, compared with cells from healthy subjects, DMD-hMDSCs are primed to self-differentiate in growth-inducing medium (GM) and robustly differentiate into myotubes in differentiat...
The myogenesis activation in DMD-hMDSCs demonstrated in this study may provide novel mechanistic insights into DMD pathogenesis and potential therapies....
Injury to skeletal muscle through trauma, physical activity, or disease initiates a process called muscle regeneration. When injured myofibers undergo necrosis, muscle regeneration gives rise to myofi...
Skeletal muscle myogenesis represents one of the most intensively and extensively examined systems of cell differentiation, tissue formation, and regeneration. Muscle regeneration provides an in vivo ...
The prevalence of idiopathic scoliosis (IS) is 2-3% worldwide and is more common in girls. Estrogen receptors (ERs) is supposed to be related to sex differences and development of IS. Meanwhile, parav...
The AP-1 transcription factor, FBJ osteosarcoma oncogene (FOS), is induced in adult muscle satellite cells (SCs) within hours following muscle damage and is required for effective stem cell activation...
We established an inducible, FOS expression system to evaluate the impact of persistent FOS activity in muscle progenitor cells ex vivo. We performed various assays to measure cellular proliferation a...
Persistent FOS activity in primary muscle progenitor cells severely antagonizes their ability to differentiate and form myotubes within the first 2 weeks in culture. RNA-seq analysis revealed that ect...
Our results suggest that elevated FOS activity in recently activated muscle progenitor cells perturbs cellular differentiation by altering the 3D chromosome organization near critical pro-myogenic gen...